Clinical Drug Investigation

, Volume 21, Issue 10, pp 679–684 | Cite as

Antipsychotic Drug Prescription in a Serbian Long-Stay Psychiatric Care Facility

  • Slobodan M. Jankovic
  • Zoran Kovacevic
  • Snezana V. Jankovic
  • Dimitrios Kouvelas
  • P. P. Papaioannidou
  • Vassiliki Mirtsou-Fidani
Clinical Use



This study evaluated the current use of antipsychotic drugs in a long-stay psychiatric care facility.

Design and Setting

The study was a cross-sectional survey of drug therapy in a long-stay psychiatric care facility, performed in the Institute for Psychiatric Care of Adults (IPCA) in Male Pcelice, Serbia, FR Yugoslavia.


The drug therapy of 806 inpatients was surveyed.


The survey was performed on a randomly chosen day. The following data were collected from patient files and drug charts: age, gender, diagnosis, age of onset of illness, age of first hospitalisation, and current dosage of psychotropic drugs.

Main Outcome Measures

The main outcome measures were the spectrum of drugs used for a particular disorder, the number of drugs used per patient, the average dose of each drug, and the average length of therapy.


The majority of the inpatients had schizophrenia (396) or mental retardation (330). Fifteen percent of the patients did not take any psychotropic medication. Among 682 patients taking psychotropic medication, 547 (80.2%) were receiving antipsychotics. The median daily dose of antipsychotic s was 450mg of chlorpromazine (CPZ) equivalent. 133 patients (24% of those taking antipsychotics) with schizophrenia were maintained on depot antipsychotics. The dosage of antipsychotics in patients with schizophrenia was higher than that in patients with other diagnoses (median 500 vs 400mg of CPZ equivalent per day; U = 42467; p = 0.0005; significant difference). Of the patients taking antipsychotics, 237 (43.4%) were taking one, 254 (46.4%) were taking two, and 56 (10.2%) were taking three or more agents. 243 (44.4%) patients were taking an anticholinergic antiparkinsonian agent, trihexyphenidyl, in a median daily dose of 5mg. 351 (64.1%) patients were taking some other psychotropic drug. The patients receiving both antipsychotics and other psychotropic drugs were on slightly lower dosages of antipsychotics than the patients receiving antipsychotics only (median 400 vs 450mg of CPZ equivalent per day; U = 35239.8, p = 0.691; NS).


Significant irrationalities in psychotropic drug use were observed: maintenance dosages of antipsychotics were higher than those recommended by international guidelines; two or more antipsychotics were administered to an unacceptably high proportion of patients, and adjuvant psychotropic medication was overused. There is a need for translating international guidelines into Serbian to allow Serbian practitioners to prescribe psychotropic drugs in line with modern views.


Schizophrenia Clozapine Psychotropic Medication Psychotropic Drug Anticholinergic Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Scottish Intercollegiate Guidelines Network. Guidelines derived from the national clinical guidelines recommended for use in Scotland by the Scottish Intercollegiate Guidelines Network (SIGN) [online]. Available from URL: [Accessed 2001 Apr04]
  2. 2.
    American College of Physicians — American Society of Internal Medicine. Clinical Practice Guidelines. 1996–2000 [online]. Available from URL: [Accessed 2001 Apr 04]
  3. 3.
    McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999; 60(Suppl. 11): 3–80Google Scholar
  4. 4.
    Katzung BG. Basic and clinical pharmacology. 7th ed. London: Prentice-Hall International Inc, 1998Google Scholar
  5. 5.
    Jankovic SM, Milovanovic D, Ruzic D, et al. Utilisation of drugs for cardiovascular diseases in cardiological department of Clinical Hospital Center ‘Kragujevac’ in 1997. Pharmaca Iugoslavica 1998; 36: 62–5Google Scholar
  6. 6.
    Chow LY, Ungvari GS, Chiu HFK, et al. Psychotropic drug prescription for chronic psychiatric patients in a long-stay care facility. Hong Kong J Psych 1999; 9: 15–20Google Scholar
  7. 7.
    World Health Organization. ICD-10 Chapter V. Diagnostic Criteria for Research. Geneva: WHO, 1993Google Scholar
  8. 8.
    Bland M. An introduction to medical statistics. 2nd ed. Oxford: Oxford University Press, 1995Google Scholar
  9. 9.
    Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426–33PubMedGoogle Scholar
  10. 10.
    Kiivet RA, Llerena A, Dahl ML, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995; 40: 467–76PubMedCrossRefGoogle Scholar
  11. 11.
    Yip KC, Ungvari GS, Cheung HK, et al. A survey of anti-psychotic treatment for schizophrenia in Hong Kong. Chin MedJ 1997; 110: 792–6Google Scholar
  12. 12.
    Fourrier A, Gasquet I, Allicar MP. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000; 49: 80–6PubMedCrossRefGoogle Scholar
  13. 13.
    Stojiljkovic S. Psychiatry with medical psychology. 1st ed. Beograd-Zagreb: Medicinska Knjiga, 1984Google Scholar
  14. 14.
    Kecmanovic D. Psychiatry. 1st ed. Beograd-Zagreb: Medicinska Knjiga, 1984Google Scholar
  15. 15.
    Djukic Dejanovic SM, Jankovic SM. Drug therapy in psychiatry. 1st ed. Kragujevac: CHCK, 1999Google Scholar
  16. 16.
    Ambühl B, Würmle O, Michel K. Prescribing practice of psychotropic drugs in a psychiatric university clinic. Psychiatr Prax 1993; 20: 70–3PubMedGoogle Scholar
  17. 17.
    Grohmann R, Ströbel C, Rüther E, et al. Adverse psychic reactions to psychotropic drugs — a report from the AMUP study. Pharmacopsychiatry 1993; 26: 84–93PubMedCrossRefGoogle Scholar
  18. 18.
    Baldessarini RJ, Kando JC, Centorrino F. Hospital use of anti-psychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 1995; 152: 1038–44PubMedGoogle Scholar
  19. 19.
    Shen WW. Pharmacotherapy of schizophrenia: the American current status. Keio J Med 1994; 43: 192–200PubMedCrossRefGoogle Scholar
  20. 20.
    Jankovic SM. Handbook of pharmacology. 2nd ed. Kragujevac: Medical Faculty, 1999Google Scholar
  21. 21.
    Picone DA, DMello DA, Foote ML, et al. A review of the utilization of sedative-hypnotic drugs in a general hospital. Gen Hosp Psychiatry 1993; 15: 51–4PubMedCrossRefGoogle Scholar
  22. 22.
    Miljkovic M, Djukic Lj. Analysis of drug utilization in Serbia during the years 1996 and 1997. Pharmacoepidemiol Drug Saf 2000; 9: 59–64CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Slobodan M. Jankovic
    • 1
  • Zoran Kovacevic
    • 1
  • Snezana V. Jankovic
    • 1
  • Dimitrios Kouvelas
    • 2
  • P. P. Papaioannidou
    • 2
  • Vassiliki Mirtsou-Fidani
    • 2
  1. 1.Department of PharmacologyMedical FacultyKragujevac
  2. 2.Department of PharmacologyAristotle University of ThessalonikiGreece

Personalised recommendations